RVMD Revolution Medicines Inc

$RVMD $SLS $XBI Once the frontline Q4 AML readout lands as a definitive success, the subsequent clinical expansion into major solid tumor indications will be blindingly fast. Because the safety and pharmacokinetic logs are already validated during the hematological trials, pivoting the asset into pancreatic, ovarian, and lung tumor protocols becomes an incredibly lean, highly accelerated regulatory pipeline. SELLAS will expand its total addressable market exponentially at a fraction of the traditional cost, forcing Big Pharma to negotiate against a conjoined WT1/CDK9 portfolio. “Strong Presence” at ASH? The new standard of care is already locked inside the box. AML and beyond 🚨💎🔥

$RVMD $SLS $XBI In patient-derived, MYC-amplified pancreatic tumor organoids completely resistant to RVMD's frontrunner, the single-agent activity numbers told the whole story: • Daraxonrasib (RVMD) Alone: Negligible 2.8% apoptosis / 2.7% necrosis. • SLS009 Alone: Impressive 17.9% apoptosis / 14.5% necrosis—proving independent single-agent efficacy in a completely resistant setting. • The Combination Synergy (RVMD + SLS009): Pushed tumor cell destruction to a massive 36.5% apoptosis / 30.6% necrosis. Any Big Pharma powerhouse building out a multi-billion-dollar RAS portfolio must find a way to plug the MCL-1/c-MYC escape hatch to prevent patient relapse. With the international patent filings locked on October 12 covering the use of the drug in high-risk ASXL1 genetic profiles across all hematological and solid tumors, no mega-cap buyer can touch this mechanism without cutting a multi-billion-dollar check to SELLAS.

$RVMD H.C. Wainwright ($350.00) and Evercore ISI ($340.00), while the lowest active target sits at $179.00 RBC Capital Markets Outperform $321.00 Brookline Capital Markets Buy $318.00. Truist Securities Buy $261.00 Oppenheimer Outperform $260.00 Morgan Stanley Overweight $255.00 Piper Sandler Overweight $222.00

$RVMD $SLS Revolution Medicines (RVMD) stock has shown a well-documented run-up in its price per share (PPS) leading up to its clinical data release at ASCO 2026 from low of $45 to high of $224.00 ✌️🙏❤️‍🩹

$RVMD $SLS I bought $RVMD at $49.85 before data and it went to $224 after data. I sold all my shares at $130 as documented here and bought more $SLS. $RVMD went from MC of little over $8 Billion to $45 Billion post ASCO 2026 presentation. ✌️🙏❤️‍🩹

$RVMD $SLS $MRNA Both RVMD and Moderna PPS went 10 times after phase 3 cancer drugs results. Sellas Next up!✌️🙏❤️‍🩹

$RVMD receives a positive CHMP opinion for RASONQUE, a first-in-EU RAS-targeted therapy for metastatic pancreatic cancer.

$RVMD No clue what tomorrow will bring, but long-term this company will be worth more than $MRNA

$RVMD there is a scenario rasonque could be the only ras inhibitor on the market for 5+ years! That’s huge and the landscape crowd may never make it or be delayed. $RVMD is severely undervalued in this case 304 by February

$RVMD JPM raised their target to $ 289 from $ 246 so I assume they will be highlighting the company at the Healthcare JPM conference in early January.

$RVMD $SLS $XBI this is 100% true, i posted a few similar DDs before on this one, merk no.1 drug expanded to 13+ more cancers applications within 3 years after first approval...

$RVMD These two chart show the price action on RVMD over three months and over 7 days, each diamond shows a sweep order greater than $2MILL. there was about 13 of these over the past three months until yesterday when there was 23 alone all near the lows. They are loading up on this stock, it may hang around here for a few days but not for long IMO

$RVMD yea yea galea same nonsense and all within trading range lol, picked up 180 Jan calls

$RVMD this one is one that will be interesting. Market is crashing and pulling everything with it. Have to wait for the overall market to find a floor then I will buy in

$RVMD reports third quarter results tomorrow, November 4. Rasonque nearly doubled survival in metastatic pancreatic cancer after chemotherapy failed, 13.2 versus 6.7 months in Phase 3, published in the New England Journal of Medicine. Next to watch: the European approval decision

$RVMD you should add, soon earning will show how the sale are out of control and europeen approval is in November

$RVMD It looks like it will be long term now lol. I actually dont mind. But im all in here so no more money to buy dips unless i borrow lol.

$RVMD Medium to long term this company and stock will do great. Price just got a little bit ahead of itself but I’m buying into this correction….

$RVMD Blew $25M estimates out of the water with $197M revenue. Rasonque launch may go down as best in history of biotech.

$RVMD Earnings Nov 4: the first full quarter of Rasonque sales in pancreatic cancer after chemotherapy. Survival 13.2 vs 6.7 months in Phase 3. New patient starts are the number to watch.